Genexine, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported negative sales was KRW 0.0001 million compared to sales of KRW 0.00035 million a year ago. Net loss was KRW 20,935.22 million compared to KRW 18,788.56 million a year ago. Basic loss per share from continuing operations was KRW 504 compared to KRW 574.6154 a year ago. Diluted loss per share from continuing operations was KRW 504 compared to KRW 574.6154 a year ago. Basic loss per share was KRW 504 compared to KRW 747 a year ago.
For the nine months, sales was KRW 7 million compared to KRW 4.72 million a year ago. Net loss was KRW 69,463.19 million compared to KRW 17,609.19 million a year ago. Basic loss per share from continuing operations was KRW 1,728 compared to KRW 540 a year ago. Diluted loss per share from continuing operations was KRW 1,728 compared to KRW 540 a year ago. Basic loss per share was KRW 1,728 compared to KRW 702 a year ago.